Stocktoria
Laboratorios Farmaceuticos Rovi, S.A. ROVI.MC
Laboratorios Farmaceuticos Rovi, S.A. (ROVI.MC) earns a Piotroski F-score of 7/9 (strong financial health), with an Altman Z″ in the safe zone. It pays a dividend yielding 1.63% (safety: safe). FY2025 revenue was €743.5M at a 18.9% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Healthcare · percentile among 79 companies
Percentile vs other Healthcare companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 7/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.403 |
| Retained earnings / assets | 0.605 |
| EBIT / assets | 0.194 |
| Equity / liabilities | 2.371 |
About Laboratorios Farmaceuticos Rovi, S.A.
Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express; catheter care under the Fibrilin brand; and Sodium Heparin Rovi. In addition, the company offers contract-manufacturing services comprising compounding, sterile filling and terminal sterilisation, inspection, installation of safety devices, labelling, packaging, serialisation and aggregation, for different injectable pharmaceutical forms, such as prefilled syringes, vials and cartridges, as well as manufacturing and packaging services for solid products. Further, it offers low-molecular-weight heparin, Okedi, and Rolcya; and develops Letrozole SIE and Risperidone QUAR. Its products are used for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. The company was incorporated in 1946 and is headquartered in Pozuelo de Alarcón, Spain. Laboratorios Farmaceúticos Rovi, S.A. operates as a subsidiary of Norbel Inversiones, S.L.
FAQ
Is ROVI.MC financially healthy?
Laboratorios Farmaceuticos Rovi, S.A.'s Piotroski F-score is 7/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does ROVI.MC pay a dividend, and is it safe?
Yes. Laboratorios Farmaceuticos Rovi, S.A. pays a dividend yielding about 1.63% with a 34.1% payout ratio, rated “safe” for safety.
How profitable is ROVI.MC?
In FY2025, Laboratorios Farmaceuticos Rovi, S.A. had a net margin of 18.9% and a return on equity of 21.1%.
Is ROVI.MC overvalued or undervalued?
Laboratorios Farmaceuticos Rovi, S.A. trades at about 20.9× trailing earnings — below its 10-year norm (10-year range 10.4×–26.1×, median 24.5×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for ROVI.MC?
The average Wall-Street price target for Laboratorios Farmaceuticos Rovi, S.A. is €75.38, about 31.3% above the recent price, from 9 analysts.
Is ROVI.MC a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Laboratorios Farmaceuticos Rovi, S.A.: a Piotroski F-score of 7/9, an Altman Z″ in the safe zone, a P/E of about 20.9×, a dividend yield of 1.63%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · ES · as of 2025-12-31. Figures in EUR. Facts plus Stocktoria's own computed scores — not investment advice.